This CME/CE program will highlight recent advances in disease management of generalized myasthenia gravis (MG) by reducing levels of IgG autoantibodies. The expert faculty, led by Dr. James F. Howard, will first cover the pathophysiology of MG, including therapeutic approaches and general limitations for current immunosuppressant therapies. Following, current clinical trial data of FcRn Inhibitors in myasthenia gravis will be analyzed, along with therapies in the pipeline. The faculty will conclude with a discussion of practical considerations for implementing tailored treatment plans in practice. Upon conclusion of this program, clinicians will be better equipped to treat and manage their patients with MG.
MG and other neuromuscular disease specialists, neuroimmunologists, general neurologists, other clinicians who manage patients with MG
- Understand the pathophysiology of generalized myasthenia gravis and the rationale for targeted, non-steroidal immune-mediated therapy
- Explain the mechanism of action of FcRn inhibitors in MG and review recent clinical trial data
- Plan implementation of therapy with emerging and approved FcRn inhibitors into current treatment guidance for individualized management of generalized MG by the interprofessional team
I. Pathophysiology of Generalized Myasthenia Gravis and the Rationale for Targeted, Non-Steroidal Immune-Mediated Therapy – John Vissing, MD
II. FcRn inhibitors in MG: Mechanism of Action, Clinical Trial Data – James F. Howard Jr., MD
III. Implementation of Therapy with Emerging and Approved Novel Agents for Individualized Management of Generalized MG by the Interprofessional Team –
Vera Bril, MD
IV. Interactive Panel Discussion – All Faculty
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|James F. Howard Jr., MD (Course Chair)||Consultant/Advisor: Alexion Pharmaceuticals, Inc.; argenX; Horizon Therapeutics plc; Immunovant, Inc.; Ra Pharmaceuticals; Regeneron Pharmaceuticals Inc.; Sanofi-Aventis U.S. LLC; Toleranzia AB; UCB S.A.; Viela Bio, Inc.
Research/Grant Support: Alexion Pharmaceuticals, Inc.; argenX; Cartesian Therapeutics; The Centers for Disease Control and Prevention; Millennium Pharmaceuticals; National Institutes of Health; Patient-Centered Outcomes Research Institute; Ra Pharmaceuticals; UCB S.A.
Stock: Johnson & Johnson Services, Inc.; Pfizer Inc.; GlaxoSmithKline; General Electric
|Vera Bril, MD||Consultant/Advisor: Alexion Pharmaceuticals, Inc.; Alnylam Pharmaceuticals, Inc; argenX; Akcea Therapeutics; CSL; Immunovant, Inc.; Ionis Pharmaceuticals; Janssen Global Services, LLC; Momenta Pharmaceuticals, Inc.; Roche; Takeda Pharmaceutical Company Limited
Research/Grant Support: Alexion Pharmaceuticals, Inc.; Immunovant, Inc.; Ionis Pharmaceuticals; Takeda Pharmaceutical Company Limited; UCB S.A.
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Benedek and Nicole McMenamin state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an educational grant from argenX.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and argenX do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 80% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].